Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Stuttgart – page 68

982 clinical trials in Stuttgart, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Stuttgart at a glance
982
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

982 trials in Stuttgart

Open in trial search

Gastrointestinal melanoma+7

Not recruiting

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.

Prostate cancer metastatic

Not recruiting

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Growth hormone deficiency

Not recruiting

Study on the Effects of Somapacitan and Somatropin in Children with Growth Hormone Deficiency

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Non-small cell lung cancer

Not recruiting

Study on the Effectiveness and Safety of Alectinib, Entrectinib, and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Not recruiting

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Effects and Safety of Riliprubart for Patients with Chronic Inflammatory Demyelinating Polyneuropathy Unresponsive to Usual Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Pulmonary embolism

Not recruiting

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Assistance Publique Hopitaux De Paris

Clear cell papillary renal cell carcinoma

Not recruiting

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Chronic myeloid leukaemia

Not recruiting

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer+2

Not recruiting

Study on the Safety of Osimertinib with Radiation for Patients with Stage IV EGFR-Mutation Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AIO-Studien gGmbH

Hormone-dependent prostate cancer

Not recruiting

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Stuttgart

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic prostate cancer, diffuse large B-cell lymphoma, and bladder cancer treatments. Studies evaluate novel therapeutic approaches including targeted therapies and immunotherapy combinations.

  • Advanced Cancer Treatments
  • Immunotherapy Studies
  • Novel Drug Combinations

Several trials investigating breakthrough treatments for various forms of leukemia and solid tumors.

02 Immunology and Vaccines

Research focusing on cytomegalovirus prevention and influenza vaccination in different age groups. Studies evaluate innovative vaccine formulations and immune responses.

  • Vaccine Development
  • Immune Response Studies
  • Preventive Medicine

Trials aim to enhance vaccine efficacy and improve protection against infectious diseases.

03 Metabolic and Eye Disorders

Studies addressing weight management and various eye conditions including retinal disorders. Research includes innovative treatments for macular degeneration and vision preservation.

  • Weight Management Therapies
  • Retinal Disease Treatment
  • Vision Preservation

Focus on developing treatments that improve patient outcomes and quality of life.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.